Artemisinin-based Combination Therapies (ACTs) remain the first-line treatment for uncomplicated Plasmodium falciparum malaria in Senegal. The recent emergence of World Health Organization (WHO)-validated Pfkelch13 (K13) mutations associated with artemisinin partial resistance in Africa highlights the need for continuous molecular surveillance. We conducted a nationwidegenomic surveillance study of 3,800 P.
First Detection of WHO-validated artemisinin resistance Plasmodium falciparum K13 C469Y mutation in patient from Senegal.
calendar_today
September 11, 2026
person
Gaye, A., Ngom, B., Sow, D., Sene, A., Toure, M., Tine, A., Ndiaye, Y. D., Dieye, B., Diongue, K., Diedhiou, Y., Ndiaye, M. F., Ndiaye, M., Mbaye, A. M., Thiongane, A., Standeur, N. K., Ndiaye, L., Zoumarou, D., Gomis, J. F., Seck, M. C., Ndiaye, I. M., Diallo, I., Doucoure, E., Diop, N. C., Dia, A. K., Badiane, A. S., Diallo, M. A., Deme, A. B., Ndiaye, D.
domain
medrxiv